monomethyl 2,3-O-isopropylidene tartrate | 143004-82-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: monomethyl 2,3-O-isopropylidene tartrate
• 英文别名: (R,R)-2,2-Dimethyl-1,3-dioxolane-4,5-dicarboxylic acid, monomethyl ester；2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylic acid monomethyl ester；5-(Methoxycarbonyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid；5-methoxycarbonyl-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid
• CAS: 143004-82-4
• 化学式: C₈H₁₂O₆
• 分子量: 204.18
• InChiKey: QDCLIEXYHDLWGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  monomethyl 2,3-O-isopropylidene tartrate 、 S-methyl N-phenylbenzenecarboximidothioate 在 二氯磷酸苯酯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以25%的产率得到3(RS),4(RS),5(RS)-1,4-diphenyl-4-methylthio-3(4')spiro-(2',2'-dimethyl-5'-methoxycarbonyl-1',3'-dioxolane)-2-azetidinone
  参考文献：
  名称：

  异构螺-β-内酰胺的结构研究：核磁共振和 X 射线研究

  摘要：

  摘要 1,4-二苯基-4-甲硫基-3(4')螺-(2',2')-二甲基-5'-甲氧基-羰基-1',3'-二氧戊环)-2-氮杂环丁酮的两种非对映异构体已通过 1 H 和 13 C NMR 和结构 X 射线衍射方法合成和研究。异构体 3( SR ), 4( RS ), 5( RS ) ( I ) 在三斜晶系中结晶, 空间群 P 1 , 晶胞尺寸 α = 9.000(4), b = 9.606(2), c = 13.861 (2) A, α = 104.44(2)°；β = 107.06(2)°，γ = 100.28(3)°，Z = 2；异构体 3( RS ), 4( RS ), 5( RS ) ( II ) 在单斜晶系中结晶, 空间群 P 2 1 / n , 晶胞尺寸 α = 9.642(1), b = 33.631(4), c = 12.967(1) A, β = 96.766(8)° 和 Z

  DOI：

  10.1016/0022-2860(92)80011-6
• 作为产物：
  描述：

  2,3-O-异亚丙基-D-酒石酸二甲酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 monomethyl 2,3-O-isopropylidene tartrate
  参考文献：
  名称：

  EP1415983

  摘要：

  公开号：

文献信息

• 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor
  申请人：Okazaki Kosuke

  公开号：US20060111446A1

  公开（公告）日：2006-05-25

  The present invention relates to a 5-amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R 1 is a hydrogen atom or a lower alkyl group; R 2 represents a hydrogen atom, an optionally substituted lower alkyl group, etc.; R 3 is a di(lower alkyl)amino group, a lower alkyl group, a cycloalkyl group, etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group, etc., or a pharmaceutically acceptable salt thereof, which exerts a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same, a pharmaceutical use thereof and an intermediate thereof.

  本发明涉及一种5-酰胺基-N-(2-氨基苯乙基)-2-羟基苯磺酰胺衍生物，其通式表示为：其中R1为氢原子或低碳基；R2表示氢原子、可选取代的低碳基等；R3为二(低碳基)氨基基团、低碳基、环烷基等；Q为氢原子或可选取代的低碳基；Z为氢原子或羟基等，或其药学上可接受的盐，具有强效和选择性的激活血凝因子X抑制活性，并可用作预防或治疗与激活血凝因子X相关的疾病的药物，以及包含该药物的制药组合物、其药用和中间体。
• 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor
  申请人：——

  公开号：US20040242455A1

  公开（公告）日：2004-12-02

  The present invention relates to a 5-amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative represented by the general formula: 1 wherein R 1 is a hydrogen atom or a lower alkyl group; R 2 represents a hydrogen atom, an optionally substituted lower alkyl group, etc.; R 3 is a di(lower alkyl)amino group, a lower alkyl group, a cycloalkyl group, etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group, etc., or a pharmaceutically acceptable salt thereof, which exerts a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same, a pharmaceutical use thereof and an intermediate thereof.

  本发明涉及一种由通式1表示的5-酰胺基-N-(2-氨基苯乙基)-2-羟基苯磺酰胺衍生物，其中R1是氢原子或较低的烷基；R2表示氢原子、可选取代的较低烷基等；R3是二(较低烷基)氨基基团、较低烷基基团、环烷基等；Q是氢原子或可选取代的较低烷基；Z是氢原子或羟基等，或其药学上可接受的盐，该化合物具有强效和选择性的激活血凝因子X抑制活性，并可用作预防或治疗与激活血凝因子X相关的疾病的药物，以及包含该化合物的制药组合物、其药物用途和中间体。
• Compounds for the treatment of inflammatory disorders
  申请人：Siddiqui Arshad M.

  公开号：US20060178366A1

  公开（公告）日：2006-08-10

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及式（I）的化合物：或其药学上可接受的盐、溶剂或异构体，可用于治疗由MMPs、aggrecanase、ADMP、LpxC、ADAMs、TACE、TNF-α或其组合介导的疾病或病况。
• Compounds for the treatment of inflammatory disorders and microbial diseases
  申请人：Siddiqui Arshad M.

  公开号：US20070167426A1

  公开（公告）日：2007-07-19

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及式(I)的化合物：或其药学上可接受的盐、溶剂或异构体，可用于治疗由MMPs、aggrecanase、ADMP、LpxC、ADAMs、TACE、TNF-α或其组合介导的疾病或病况。
• COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Guo Zhuyan

  公开号：US20100145048A1

  公开（公告）日：2010-06-10

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及公式(I)的化合物：或其药学上可接受的盐、溶剂化合物或异构体，可用于治疗由MMPs、ADAMs、TACE、TNF-α或其组合介导的疾病或病症。